1. Home
  2. TISI vs ALXO Comparison

TISI vs ALXO Comparison

Compare TISI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Team Inc.

TISI

Team Inc.

HOLD

Current Price

$14.40

Market Cap

66.9M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.18

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TISI
ALXO
Founded
1973
2015
Country
United States
United States
Employees
6800
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.9M
68.3M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
TISI
ALXO
Price
$14.40
$2.18
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.42
AVG Volume (30 Days)
2.7K
1.0M
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
50.12
31.02
EPS
N/A
N/A
Revenue
$852,272,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.34
$0.41
52 Week High
$24.20
$2.66

Technical Indicators

Market Signals
Indicator
TISI
ALXO
Relative Strength Index (RSI) 51.37 52.88
Support Level $13.48 $1.41
Resistance Level $15.00 $2.27
Average True Range (ATR) 0.48 0.25
MACD 0.02 -0.07
Stochastic Oscillator 42.42 24.62

Price Performance

Historical Comparison
TISI
ALXO

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: